Retatrutide Research for Type 2 Diabetes
An evidence-based overview of research examining Retatrutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 trials demonstrated exceptional glycemic control with HbA1c reductions of up to 2.02% at the 12mg dose (36 weeks), compared to essentially no change with placebo. An remarkable 82% of patients achieved HbA1c levels of 6.5% or below with concurrent weight loss of 16.9%.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Retatrutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.